Bristol-Myers Squibb & Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) & VE800 in Pa...

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma. This indication is approved under accelerated approv...